Lisata shares pipeline update of anticancer lead candidate drug
Lisata aims to finish enrolment of its Phase II trial in solid tumours by the end of 2024, with plans for a further study later this year.
Lisata aims to finish enrolment of its Phase II trial in solid tumours by the end of 2024, with plans for a further study later this year.
What's Your Reaction?
